Steven James Biography and Net Worth

Director of Allakos


Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is president and Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).

How do I contact Steven P. James?

The corporate mailing address for Mr. James and other Allakos executives is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. Allakos can also be reached via phone at (650) 597-5002 and via email at [email protected]. Learn More on Steven P. James' contact information.

Has Steven P. James been buying or selling shares of Allakos?

Steven P. James has not been actively trading shares of Allakos in the last ninety days. Most recently, Steven P. James sold 4,000 shares of the business's stock in a transaction on Tuesday, September 28th. The shares were sold at an average price of $108.12, for a transaction totalling $432,480.00. Learn More on Steven P. James' trading history.

Who are Allakos' active insiders?

Allakos' insider roster includes Robert Alexander (CEO), Peter Hudson (Major Shareholder), Steven James (Director), Daniel Janney (Director), Robert More (Major Shareholder), Henrik Rassmussen (Insider), and Adam Tomasi (COO). Learn More on Allakos' active insiders.

Steven P. James Insider Trading History at Allakos

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/28/2021Sell4,000$108.12$432,480.00View SEC Filing Icon  
See Full Table

Steven P. James Buying and Selling Activity at Allakos

This chart shows Steven P James's buying and selling at Allakos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Allakos Company Overview

Allakos logo
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $1.26
Low: $1.26
High: $1.32

50 Day Range

MA: $1.33
Low: $1.16
High: $1.64

2 Week Range

Now: $1.26
Low: $1.00
High: $5.64

Volume

524,912 shs

Average Volume

643,913 shs

Market Capitalization

$110.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83